By Onco'Zine Staff Writer
Surgical complications can substantially increase costs in cancer care, but improvements in patient safety, by reducing common errors, may be able to improve the quality of healthcare.
According to a new study published online December 30, 2013, in Cancer, The Journal of the American Cancer Society, researchers from Rice University's Baker Institute for Public Policy and the University…Continue
Added by Editorial Team on January 20, 2014 at 10:00am — No Comments
Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy. Such newly, refined classification of different tumor subtypes will ultimately facilitate more effective treatment tailored to a specific tumor as well as…Continue
Added by Editorial Team on January 17, 2014 at 6:30pm — No Comments
Fifty years after the original landmark report of the United StatesSurgeon General’s Advisory Committee on Smoking and Health, a new report, published today, the 32nd tobacco-related Surgeon General’s report issued since 1964, highlights both the dramatic progress the United States has made reducing tobacco use and the continuing burden of disease and death caused by the vice of smoking. The new report called:…Continue
Added by Editorial Team on January 17, 2014 at 5:00pm — No Comments
By Onco'Zine Staff Writer
Researchers at the Yale University School of Public Health, New Haven, Connecticut estimate that tobacco control in the United States since 1964 has been associated with the avoidance of an estimated 8 million premature smoking-attributable deaths, with the beneficiaries of these avoided early deaths having gained, on average, nearly 2 decades of life. In their study, which was…Continue
Added by Editorial Team on January 10, 2014 at 5:30pm — No Comments
Each year, more than 440,000 Americans die from smoking. Eight million Americans live with at least one serious chronic disease from smoking. The cost to U.S economy is $193 billion a year, with nearly $96 billion in direct medical costs and an additional $97 billion in lost productivity. But change is looming on the horizon.
January 2014 marks the 50th anniversary of the first Surgeon General's report on Smoking and Health. On January 11, 1964, Luther L. Terry,…Continue
Added by Peter Hofland, PhD on January 10, 2014 at 2:30pm — No Comments
By Onco'Zine Staff Wiriter
A nomogram that incorporates factors such as age, Gleason score, and prostate-specific antigen (PSA) level at diagnosis may be able to estimate if a screen-detected prostate cancer has been overdiagnosed according to a new study published January 6 in the Journal of the National Cancer Institute.
Researchers developed the over-diagnosis nomogram to assist both patients and clinicians…Continue
Added by Editorial Team on January 10, 2014 at 9:00am — No Comments
The PANcreatic Cancer RadioImmunotherapy Trial-1 (PANCRIT-1) starts its patient accrual phase. This trial is a double-blind, randomized study and will enroll approximately 440 patients with metastatic pancreatic cancer. A majority of patients will be recruited at clinical trial sites across the United States, with additional sites in Canada, Europe and Israel participating. Eligible patients will be randomized 2 to 1 to the treatment arm of 3 doses of 90Y-clivatuzumab tetraxetan (…Continue
Added by Peter Hofland, PhD on January 9, 2014 at 8:30pm — No Comments
The U.S. Food and Drug Administration (U.S.FDA) has approved trametinib (Mekinist®; Glaxosmithkline/GSK) for use in combination with dabrafenib (Tafinlar®;Glaxosmithkline/GSK) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved companion…Continue
Added by Peter Hofland, PhD on January 9, 2014 at 5:30pm — No Comments
An Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III Resonate™ trial, a head-to-head comparison of Ibrutinib (PCI-32765, Imbruvica®; Pharmacyclics) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met.
Resonate is a randomized, multicenter, open-label Phase…Continue
Added by Peter Hofland, PhD on January 7, 2014 at 9:00pm — No Comments
Researchers at the University of Cincinnati (UC) Cancer Institute have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer (NSCLC) with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with that condition.
These findings are presented via poster at the American Association for Cancer Research (AACR)–International Association for the…Continue
Added by Peter Hofland, PhD on January 7, 2014 at 4:00pm — No Comments
In many types of cancer cells from the primary tumor can intravasate into the bloodstream as circulating tumor cells or CTCs. These CTCs can then interact with the receptor-bearing endothelial cell wall. The process is similar to leukocyte extravasation - the flow of blood or lymph-fluid into surrounding tissue during inflammation.
Now for the first time biomedical engineers at Cornell University inIthaca in New York, NY have discovered a new way to destroy these…Continue
Added by Peter Hofland, PhD on January 6, 2014 at 4:00pm — No Comments
Targeting cancer stem cells (CSCs) - cells from which malignant brain tumors are believed to originate and regenerate- with immunotherapy may be an effective means to prevent recurrences in glioblastoma multiforme (GBM). Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of…Continue
Added by Peter Hofland, PhD on January 6, 2014 at 3:00pm — No Comments